登录  
 加关注
查看详情
   显示下一条  |  关闭
温馨提示!由于新浪微博认证机制调整,您的新浪微博帐号绑定已过期,请重新绑定!立即重新绑定新浪微博》  |  关闭

青山妩媚

新的一年,新的心情,新的挑战,新的起点...

 
 
 

日志

 
 

Chinese Pharmaceutical Market Outlook 2009-2024  

2009-10-21 23:31:14|  分类: Bio-Pharma |  标签: |举报 |字号 订阅

  下载LOFTER 我的照片书  |

Chinese Pharmaceutical Market Outlook 2009-2024

In November 2008, China announced a major economic stimulus package, including $124bn to be spent on healthcare. These changes will have a major impact on the Chinese pharmaceutical landscape over the next 15 years, as the stimulus increases the number of clinics in rural areas, dissociates pharmacies from hospitals and promises healthcare coverage to 100% of the population by 2020. This report – Chinese Pharmaceutical Market Outlook 2009-2024 – analyses prospects for the pharma market and industry sector in China. This new study discusses market drivers and restraints such as production capacity, intellectual property rights and the high, fast-growing healthcare demands in China. Importantly, we provide detailed sales forecasting at the core of the analyses.

As both a large producer and consumer of a wide range of medicines, China is now a crucial player in the global pharmaceutical market and industry. China is still a challenging environment for foreign companies, investors and purchasers. Will the great potential benefits offered by China outweigh its drawbacks as a pharma market? Yes they will - but how and why? Read this report to find out.

China's rising significance in the global pharma market will make it a vital market for international pharmaceutical companies to enter and expand. China’s efforts to reinvent its healthcare system will change the way pharmaceuticals are marketed and sold throughout the country. However, those changes will not take place immediately. What will happen first? For example, how will prescription of antibiotics change? Also, what impact will reported quality concerns and counterfeiting have on China’s pharmaceutical sector?

Comprehensive analysis of the Chinese pharma sector

Chinese Pharmaceutical Market Outlook 2009-2024 examines that sector critically, through a comprehensive review of information sources. This report provides detailed sales forecasts, discussions of developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 70 tables and figures and a full interview transcript from our survey. The result is a comprehensive market- and industry-centred report, with detailed analyses and informed opinion to benefit your work.

Table of Contents

1 Executive Summary
1.1 Crucial Aspects of this Report
1.1.1 China's Economy: Growing Despite Credit Crisis
1.1.2 China's Healthcare Stimulus
1.2 Aims, Scope and Format of this Report
1.2.1 China: The Market to Watch Carefully
1.2.2 Contents Breakdown: Four Types of Forecasts
1.2.3 Chapter Outline
1.3 Research Methods

2 Chinese Market Overview
2.1 Whole-Market Forecast, 2009-2024 ($bn)
2.2 China's $124bn Healthcare Stimulus for 2009-2020
2.3 Sectors Most Likely to Benefit from the Healthcare Stimulus Plan
2.4 Visiongain's Assessment of the Impact of the Healthcare Stimulus Plan on Pharmaceutical Sales
2.4.1 The Impact of Separating Pharmacies from Hospitals
2.4.2 The Need to Support Hospitals
2.5 Pricing Policies (Pre-Stimulus Reform)
2.5.1 Price Controls Set by National Reform and Development Commission
2.5.2 Critiques of Price-Control Effectiveness
2.5.3 Subsidised Drugs
2.5.4 Patient-Level Prices: Producers Receive Under 40%
2.5.5 Sales of Prescription Drugs
2.6 China: Predicted to Have Largest World Economy by 2040
2.7 Brief Overview of China's Healthcare Situation
2.8 China's Healthcare Costs: Some Crucial Data
2.9 China Seeking to Improve Research and Development Profile
2.9.1 Intellectual Property Rights: Length of Patents and Protection Situation
2.9.2 Patent-Granting Authority and Patent Life
2.9.3 Innovation Companies and Departments
2.10 Zhangjiang Hi-Tech Science Park: Doubling R&D Output in Three Years
2.10.1 R&D Tax Benefits
2.10.2 Facilitating Strategic Alliances
2.10.3 Timeline for the Zhangjiang Project
2.10.4 CROs in Zhangjiang Hi-Tech Park: Gaining Access to the European Market
2.11 Disease Burdens in China: Some Crucial Tables and Figures
2.11.1 Leading Causes of Death in China
2.11.2 Respiratory Diseases
2.11.3 Cancer
2.11.4 Diabetes
2.11.5 Obesity, Cholesterol and Cardiovascular Disease

3 Prescription Pharmaceutical Market Forecasts, 2009-2024
3.1 China: Pharma Growth Forecast 2009-2014
3.2 China: Pharma Growth Forecast 2014-2024
3.3 Pharmaceutical Market Breakdown by Categories
3.4 Antibiotics and Anti-Infectives
3.4.1 Types of Antibiotics Sold in China
3.4.2 Antibiotics: Sales Growing but Losing Market Share
3.4.3 Antibiotics Became Prescription-Only in July 2004
3.4.4 Prevalence of Adverse Reactions to Antibiotics
3.4.5 Alleged Over-Prescription Likely to Continue?
3.5 Traditional Chinese Medicines (TCMs)
3.5.1 Definition of TCM in this Report
3.5.2 TCMs: Growing Through to 2024, Though Market Share Will Diminish
3.5.3 TCMs in the Home and in Hospitals
3.5.4 TCM and Approaches to Health and National Identity
3.5.5 Perceptions of TCM versus Western Medicine: Speed and Side Effects
3.5.6 Export and Government Promotion of TCMs
3.6 Vasotherapeutics / Vasodilators
3.6.1 Retaining Market Share through to 2024
3.6.2 Drugs Included in the Vasotherapeutics Category
3.6.3 Vasotherapeutics: Promoting Vitality
3.7 Solutions
3.7.1 Products Included as "Solutions"
3.7.2 Solutions Market Growing More Quickly than the Overall Market Through to 2019, then More Slowly Through to 2024
3.7.3 Key Marketing Companies in China: Shijiazhuang No. 4 and Baxter International
3.8 Antiulcerants
3.8.1 One of the Highest Growth-Rate Categories from 2019-2024
3.8.2 Drugs Included in the Antiulcerants Category
3.8.3 Antiulcerants Pipeline
3.9 Immunostimulating Agents
3.9.1 Immunostimulating Agents: How Fast Will Market Growth Be in China?
3.9.2 The Pipeline: Promising, but Subject to High Failure Rates
3.9.3 China's Cancer Rate Rising
3.10 Diabetes Treatments
3.10.1 Sales Accelerating Through 2015 and Strong Through to 2024
3.10.2 Insulin and Antidiabetics
3.10.3 Novo Nordisk Building Insulin Factory in China
3.10.4 Novo Nordisk and Insulin: Benefiting from Intra-Country Sales
3.11 Vaccines (and Others)
3.11.1 Vaccines: An Important but Relatively Closed Market
3.11.2 China is the Largest Vaccine Consumer in the World
3.11.3 Chinese Vaccine Manufacturing
3.11.4 Chinese Vaccine Research and Development
3.11.5 Sinovac Receives Swine Flu Orders from Beijing
3.11.6 Sinovac Begins Testing H1N1 Vaccine in People
3.11.7 Swine Flu Vaccines and Hualan Biological Engineering Inc.
3.11.8 Swine Flu Vaccine Yields Accumulate Slowly

4 Generics, Branded and Over-the-Counter Drugs in China: Market Breakdown and Forecasts
4.1 Prescription Drugs: Branded versus Generics Value Forecasts, 2009-2024
4.2 Prescription Drugs: Branded versus Generics Volume Forecasts, 2009-2024
4.3 Prescription Drugs: Branded versus Generic Drugs Value as Market Share Percentage, 2009-2024
4.4 Summary Figures: Generics and Branded Drugs
4.5 OTC Market Compared to Prescription Market
4.5.1 OTC and Prescription Markets: Sales Growth from 2009
4.5.2 OTC Market Growing More Quickly than the Prescription Market Throughout the Forecast Period?
4.6 Over-the-Counter Market: How Will This Market Compare with Others in China?
4.6.1 Categories Included in Over-the-Counter Forecast

5 Multinational Corporations Investing in China
5.1 GlaxoSmithKline
5.1.1 Conducting Neurodegenerative Research in China Since 2007
5.1.2 Influenza Vaccines Joint Venture with Shenzhen Neptunus
5.2 NeoStem: Pre-Disease, Adult Stem Cell Harvesting and Storage
5.2.1 NeoStem and Enhance BioMedical Holdings Ltd (Shanghai)
5.2.2 NeoStem and Suzhou Erye Pharmaceuticals Company, Ltd
5.3 Bayer Schering Pharma: Investing in Its Third-Largest Market
5.3.1 Investing $129m in Research and Development Centre in Beijing
5.3.2 In Talks with Tsinghua University
5.4 Sanofi-Aventis
5.4.1 Influenza Vaccines Facility in Shenzhen
5.4.2 Helping to Treat Diabetes in China
5.4.3 Partnership with the Chinese Diabetes Society
5.5 Novo Nordisk: Producing Insulin in China
5.5.1 Donation of a License to Novo Nordisk's Small-Molecule Compound Library
5.6 Roche: Expanding R&D Facilities and Seeking Partnerships
5.7 AstraZeneca: Investing in R&D in China
5.7.1 Oncology R&D
5.7.2 Schizophrenia and New Drug Partnerships
5.7.3 Research Fund for COPD Research
5.8 Pfizer: Seeking Acquisitions and Partnerships in China

6 Selected Domestic Companies
6.1 Sinovac Biotech Ltd. (Beijing Kexing Bioproducts): Human Vaccine Products
6.1.1 Sinovac Receives Swine Flu Orders from Beijing
6.1.2 Sinovac's Revenues Depend on a Small Number of Products
6.1.3 Sinovac's Solvency and its R&D Power
6.2 WuXi AppTec: Leading Contract Research and Development
6.2.1 WuXi's 2008 Performance
6.2.2 Maintaining Customer Satisfaction
6.2.3 WuXi and AstraZeneca: Partnership Extended in 2008
6.3 Mindray Medical International: Medical Devices
6.3.1 Product Penetration
6.3.2 Mindray's Financial Successes: Q1 2009 Growth of Nearly 70% in International Markets
6.4 China Nepstar Chain Drugstore Ltd. (Nepstar): Moving Towards Chain-Store Pharmacies
6.4.1 Financial Performance and NYSE Listing
6.4.2 Chain Stores: The Future of Chinese Pharmacies?
6.5 Hualan Biological Engineering Inc. (Hualan Biological Engineering Ltd.): The Top Blood Product Company
6.5.1 Hualan Testing Swine Flu Vaccine: Results Expected in September 2009
6.6 Tianyin Pharmaceutical Co., Inc.: Modernised Traditional Chinese Medicine
6.6.1 Financial Performance and Expectations
6.7 Guilin Sanjin Pharmaceutical Co. Ltd.: China's First IPO in 2009
6.8 Guangzhou Pharmaceuticals Corporation / Guangzhou Pharmaceutical Company, Ltd.
6.8.1 Affiliation with BMP Sunstone Corporation / Sunstone Pharmaceuticals Co. Ltd. / BMP China
6.8.2 Guangzhou and British Company Alliance Boots plc.
6.9 China Sky One Medical, Inc.
6.9.1 China Sky One Medical's Wholly-Owned Subsidiaries
6.9.2 Financial Information: Revenues Grow 100% over Q1 2008
6.9.3 September 2008 Acquisition of Jin Chuang
6.10 Harbin Pharmaceutical Group Holding Company, Ltd.
6.11 CSPC Pharmaceutical Group Limited (CSPC Pharma)
6.11.1 Financial Summary: 48% Increase in Net Profits for First Four Months of 2009
6.11.2 Moving from APIs to Finished OTC Products
6.11.3 CSPC Pharma Patents and Pipeline
6.11.4 China Pharma Holdings: SFDA Approval for Generic Crestor Clinical Trial
6.12 China Medical Technologies: In Vitro Diagnostics Specialists
6.12.1 Financial Summary: Adjusted Income Increased 79% Year-Over-Year 2008-2009
6.13 China National Biotec Group (CNBG)
6.13.1 CNBG's Future Trajectory
6.13.2 CNBG, PATH, and Chengdu Institute of Biological Products: Advancing Cost-Effective Vaccines for the Developing World
6.14 China National Pharmaceutical Corporation (Sinopharm): Holding the Nation's Medicines Reserve
6.15 Shenyang Sunshine Pharmaceutical Company Limited (Sunshine)
6.15.1 Financial Summary: First Quarter 2009 Net Revenues Increase 23.7% over First Quarter 2009

7 Chinese Market Conditions: Drivers and Restraints
7.1 Strengths and Weaknesses
7.2 Opportunities and Threats
7.3 Market Highly Fragmented: 3000-6000 Manufacturers and 15,000 Distributors
7.3.1 Nepstar and the Chain Store Pharmacy: Changing the Nature of Distribution?
7.3.2 API Companies: Moving Towards Vertical Integration
7.4 Moves Towards Greater Privatisation
7.5 Mandatory Pricing Schemes / Price Controls
7.5.1 Applications for Independent Pricing: Affecting Drugs' Perceived and Market Values
7.5.2 The 2006 Anti-Corruption Campaign and Prescribing Practices
7.6 Active Pharmaceutical Ingredients (APIs)
7.6.1 Proximal Production
7.6.2 Active Pharmaceutical Ingredients: Oversight and Quality Control
7.6.3 International and Domestic Concerns about API Quality
7.6.4 Multinational Corporations Building Their Own Factories
7.7 Counterfeit Drugs: A Continuing Problem
7.7.1 Pfizer's 2003 Anti-Counterfeiting Scheme in Shanghai
7.7.2 Counterfeits and the Internet
7.7.3 Discovery of Counterfeits in Legitimate Distribution Channels
7.8 Generics Spreading Abroad: China is Poised to Provide
7.8.1 Safety Questions: Slowing Generics Exports?
7.9 Intellectual Property Rights / Laws: Improving Protection
7.9.1 Lack of Regulatory Transparency: Another R&D Challenge in China?

8 Stem Cells in China: An Interview with Dr Stephen Minger, King’s College London, Co-Founder of the London Regenerative Medicines Network
8.1 On Why China is a Central Stem Cell Research Region
8.2 On Regulatory Conditions in China
8.3 On the Major Clinical Difference Between China and Europe/US Trials
8.4 On Laboratory Specialties
8.5 On Stem Cells Clinical Trials: Brain Cell Transplants
8.6 On Non-Approved Stem Cell Collection and Treatment Businesses
8.7 On Cord Blood and Public Stem Cells
8.8 On 'Stem Cells' as Business Buzzword
8.9 On How Stem Cell Funding is Allocated in China

9 China as a Clinical Trials Destination
9.1 International Trends Towards Outsourcing/Offshoring
9.2 China's Share of the Clinical Trials Market
9.3 China: Promising but Problematic
9.3.1 China's Market Share Growing Through to 2024
9.4 Necessary Phase III Trials in China
9.5 More International Investigation Sites Registering for FDA Approval
9.6 How Countries Invite More Trials
9.7 How Foreign Clinical Trials Help Host Countries
9.8 Continuing Challenges for Emerging Outsourcing Markets Such as China
9.9 China Pharma Holdings wins SFDA-Approval for Generic Crestor Clinical Trial
9.10 China and Generics Clinical Trials
9.11 Sundia: Ranked In Top 100 Fastest-Growing Outsourcing Service Providers
9.11.1 Sundia: Shortening Customs Times

10 Conclusions
10.1 Key Findings and Data from this Report
10.2 Summary Points
10.2.1 Drivers: Population, Domestic and Foreign Investment and Increasing Affluence
10.2.2 Restraints: Poverty, Intellectual Property and Regulatory Difficulties and Uneven Healthcare Penetration

List of Tables
Table 2.1 Chinese Whole-Market Forecast, 2009-2019 ($bn)
Table 2.2 Chinese Whole-Market Forecast, 2019-2024 ($bn)
Table 2.3 Five Policy Points of China's 2009-2011 Stimulus
Table 2.4 Pricing Rules in China (Pre-Stimulus Reforms)
Table 2.5 Top Causes of Death in China, 2002
Table 2.6 Respiratory Deaths in China by Category, 2002
Table 2.7 Cancer Deaths in China by Type, 2002 (%)
Table 2.8 Diabetes Type 2 Prevalence in China by Age Group, 2002
Table 3.1 Chinese Total Prescription Market Forecast, 2009-2019 ($bn)
Table 3.2 Chinese Total Prescription Market Forecast, 2019-2024 ($bn)
Table 3.3 Chinese Pharmaceutical Market Forecast by Drug Category, 2009-2019 ($m)
Table 3.4 Chinese Pharmaceutical Market Forecast by Drug Category, 2019-2024 ($m)
Table 3.5 Antibiotics and Anti-Infectives Forecast, 2009-2019 ($m)
Table 3.6 Antibiotics and Anti-Infectives Forecast, 2019-2024 ($m)
Table 3.7 Traditional Chinese Medicines Forecast, 2009-2014 ($m)
Table 3.8 Traditional Chinese Medicines Forecast, 2019-2024 ($m)
Table 3.9 Vasotherapeutics Forecast, 2009-2019 ($m)
Table 3.10 Vasotherapeutics Forecast, 2019-2024 ($m)
Table 3.11 Top Vasotherapeutics Sold in China, by Name and Active Ingredient, 2009
Table 3.12 Solutions Forecast, 2009-2019 ($m)
Table 3.13 Solutions Forecast, 2019-2024 ($m)
Table 3.14 Types of Solutions and Indications
Table 3.15 Antiulcerants Forecast, 2009-2019 ($m)
Table 3.16 Antiulcerants Forecast, 2019-2024 ($m)
Table 3.17 Top Antiulcerants Sold in China, by Name and Active Ingredient, 2009
Table 3.18 Immunostimulating Agents Forecast, 2009-2019 ($m)
Table 3.19 Immunostimulating Agents Forecast, 2019-2024 ($m)
Table 3.20 Diabetes Treatments Forecast, 2009-2019 ($m)
Table 3.21 Diabetes Treatments Forecast, 2019-2024 ($m)
Table 3.22 Other Pharmaceuticals Forecast, 2009-2019 ($m)
Table 3.23 Other Pharmaceuticals Forecast, 2019-2024 ($m)
Table 4.1 Branded Drugs and Generics Forecasts, 2009-2019 ($bn)
Table 4.2 Branded Drugs and Generics Forecasts, 2019-2024 ($bn)
Table 4.3 Relative CAGRs (%)
Table 4.4 Over-the-Counter Market Forecast, 2009-2019 ($bn)
Table 4.5 Over-the-Counter Market Forecast, 2019-2024 ($bn)
Table 5.1 Bayer Schering Pharma China's Business Divisions and Top 10 Products, 2009
Table 6.1 China Sky One Medical Wholly-Owned Subsidiaries
Table 6.2 Sinopharm's Wholly-Owned Subsidiaries
Table 6.3 Sinopharm's Major Joint Ventures
Table 7.1 Strengths and Weaknesses of the Chinese Market, 2009
Table 7.2 Opportunities In and Threats to the Market, 2009-2024
Table 9.1 Clinical Trials: Total Market and China Forecasts, 2009-2024 ($m)
Table 9.2 Costs and Benefits of Conducting Clinical Trials in China
Table 9.3 Some Countries Actively Funding Drug Development Infrastructure
Table 9.4 Benefits and Challenges to Outsourcing Host Countries

List of Figures
Figure 2.1 Chinese Whole-Market Forecast, 2009-2024 ($bn)
Figure 2.2 Top Causes of Death in China, 2002
Figure 2.3 Respiratory Deaths in China by Category, 2002
Figure 2.4 Cancer Deaths in China by Type (%), 2002
Figure 2.5 Diabetes Type 2 Prevalence in China, 2002
Figure 3.1 Total Market Forecast, 2009-2024 ($bn)
Figure 3.2 Forecast for Three Drug Categories with 2009 Sales Over $2000m, 2009-2024 ($m)
Figure 3.3 Forecast for Five Drug Categories with 2009 Sales Under $800m, 2009-2024 ($m)
Figure 3.4 Antibiotics and Anti-Infectives Forecast, 2009-2024 ($m)
Figure 3.5 Antibiotics and Anti-infectives Category Breakdown by Value and Percentage Share, 2009 ($m, %)
Figure 3.6 Traditional Chinese Medicines Forecast, 2009-2024 ($m)
Figure 3.7 Vasotherapeutics Forecast, 2009-2024 ($m)
Figure 3.8 Solutions Forecast, 2009-2024 ($m)
Figure 3.9 Antiulcerants Forecast, 2009-2024 ($m)
Figure 3.10 Immunostimulating Agents Forecast, 2009-2024 ($m)
Figure 3.11 Diabetes Treatments Forecast, 2009-2024 ($m)
Figure 3.12 Other Pharmaceuticals Forecast, 2009-2024 ($m)
Figure 4.1 Branded Drugs and Generics Values Forecasts, 2009-2024 ($bn)
Figure 4.2 Branded Drugs and Generics Volume Forecasts, 2009-2024 (%)
Figure 4.3 Branded Drugs and Generics Value as Percentage Forecasts, 2009-2024 (%)
Figure 4.4 Comparison of Generics and Branded Drugs' Volume and Value Percentages, 2009-2024 (%)
Figure 4.5 Comparison of Generics and Branded Drugs' Volume and Value Percentages in 2009, 2014, 2019 and 2024 (%)
Figure 4.6 OTC, Prescription and Total Market Forecasts, 2009-2024 ($bn)
Figure 4.7 Over-the-Counter Market Forecast, 2009-2024 ($bn)
Figure 9.1 China: Clinical Trials Market Forecast, 2009-2024 ($m)
Figure 9.2 China: Clinical Trials Market Share Forecast, 2009-2024 (%)

Companies mentioned in this report
Abbott
Alliance Boots plc
American California Pharmaceutical Group
Apotex
AppTec Laboratory Services Inc.
Asahi Chemical
ASKA Pharmaceutical
AstraZeneca
Baxter International
Bayer Schering Pharma
Beijing Bio-Ekon Biotechnology Co. Ltd
Beijing Economic and Technological Development Area
Beijing GP Medical Technologies, Ltd.
Beijing Yuande Bio-Medical Engineering Co., Ltd
Biofarm
BMJ (British Medical Journal)
BMP China
BMP Sunstone Corporation
Bracco
Bristol-Myers Squibb
ChemPartner
Chengdu Institute of Biological Products
China Academy of Science
China Chain Stores and Franchise Association (CCSFA)
China Council for International Investment Promotion (CCIIP)
China Medical Technologies
China National Biotec Group
China National Biotec Group (CNBG)
China National Corporation of Medicines Ltd.
China National Group Corporation of Traditional & Herbal Medicine
China National Immunization Program
China National Medical Equipment Industry Corporation
China National Pharmaceutical Foreign Trade Corporation
China National Pharmaceutical Group Corporation (Sinopharm)
China National Pharmaceutical Industry Corporation Ltd.
China Nepstar Chain Drugstore Ltd. (Nepstar)
China Ostuka Pharmaceutical Co., Ltd.
China Pharma Holdings
China Pharmaceutical Advertising Company Ltd.
China Pharmaceutical Exhibition Corporation
China Pharmaceutical Group Co., Ltd (China Pharma).
China Securities Regulatory Commission
China Sky One Medical, Inc.
Chinese Diabetes Society
CMED Technologies, Ltd.
CSPC Pharmaceutical Group Limited (CSPC Pharma)
Eli Lilly
Enhance BioMedical Holdings Ltd (Shanghai)
Enhance Holding Corporation
European Agency for the Evaluation of Medicinal Products (EMEA)
Food and Drug Administration (US FDA)
Gedeon Richter
Genentech
GlaxoSmithKline
Goldman Sachs
Guangzhou Medical University
Guangzhou Pharmaceutical Company Ltd.
Guangzhou Pharmaceuticals Corporation
Guilin Sanjin Pharmaceutical Co.
Harbin First Bio-Engineering Company Limited
Harbin Medical University
Harbin Pharmaceutical Group Co. Ltd
Harbin Pharmaceutical Group Holding Company, Ltd
Harbin Tian Di Ren Medical Science and Technology Company
HB Minkang
HB.SJZ.Shenwei
HD Biosciences
Hebei Pharmaceutical Group
Heilongjiang Haina Pharmaceutical Inc.
Heilongjiang Tianlong Pharmaceutical, Inc.
HN Tongyongsany ANG
Hualan Biological Engineering Inc.
Hualan Biological Engineering Ltd.
Il Yang
IMS Health
International Federation of Pharmaceutical Manufacturers Associations (IFPMA)

Jason Soung
Jilin University
Leti
Livzon
LN. JZ Aohong
Medicilon
Merck
Millennium
Mindray Medical International
Ministry of Health (China)
National Center for Drug Screening (NCDS)
National Food and Drug Administration
National Medicine Administration
National Reform and Development Commission (NRDC)
Nature
NeoStem
New England Journal of Medicine
North East Agricultural University
Novartis
NovaSector
Novo Nordisk
Nycomed
Orexo
PATH
Peking University
Peng Lai Jin Chuang Company Pharmaceutical Company
Pfizer
Psyma Business Research China
Qingdao Huazhong Pharmaceutical Co. Ltd.
R&D-based Pharmaceutical Association Committee (RDPAC)
Roche
Rottapharm
Sanjing Pharmaceutical Co. Ltd
Sanofi Pasteur
Sanofi-Aventis
Schwabe
Shang Pharm
Shanghai Administration for Industry and Commerce
Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Shanghai Jiao Tong University
Shanghai Municipal Food and Drug Administration
Shenyang Sunshine Pharmaceutical Company Limited (Sunshine)
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd.
Shijiazhuang No. 4
Shijiazhuang Pharmaceutical Group
Sichuan Industrial Institute of Antibiotics
Sino-American Shanghai Squibb Pharmaceutical Ltd.
Sinopharm Medicine Holding Co., Ltd.
Sinopharm United Engineering Company Ltd.
Sino-Swed Pharmaceutical Corp. Ltd.
Sinovac Biotech Ltd. (Beijing Kexing Bioproducts)
Special Program for Research and Training in Tropical Diseases (WHO-affiliated)
State Food and Drug Administration (SFDA)
State Industrial Property Office (SIPO)
State Key Lab of Respiratory Disease
Sucampo
Sundia
Sunstone Pharmaceuticals Co. Ltd.
Suzhou Erye Pharmaceuticals Company, Ltd
Suzhou Capsule Co., Ltd.
Takeda
The Ministry of Labor and Social Security (MOLSS)
Tianyin Pharmaceutical Co., Inc.
Tsinghua University
Tufts Center for the Study of Drug Development (Tufts CSDD)
Weisheng
Working Group on Obesity in China
World Bank
World Health Organization
World Trade Organization
WuXi AppTec
WuXi PharmaTech Inc.
Wyeth
Xian-Janseen Pharmaceutical Ltd.
Yuhan
Zhangjiang Group
Zhangjiang Hi-Tech Park
Zhognuo
Zhongrun
Zhongrun Neimeng

  评论这张
 
阅读(752)| 评论(1)

历史上的今天

评论

<#--最新日志,群博日志--> <#--推荐日志--> <#--引用记录--> <#--博主推荐--> <#--随机阅读--> <#--首页推荐--> <#--历史上的今天--> <#--被推荐日志--> <#--上一篇,下一篇--> <#-- 热度 --> <#-- 网易新闻广告 --> <#--右边模块结构--> <#--评论模块结构--> <#--引用模块结构--> <#--博主发起的投票-->
 
 
 
 
 
 
 
 
 
 
 
 
 
 

页脚

网易公司版权所有 ©1997-2018